Movement disorders clinical practice · 2026
Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brusa Livia, Piano Carla, Casula Elias Paolo, Marano Massimo, Suppa Antonio, Zampogna Alessandro, Patera Martina, Toro Stefano, Campone Jacopo, Viselli Fabio, Vacca Laura, Alborghetti Marika, Stefani Alessandro, Bove Francesco
Аннотация
BACKGROUND: Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease (PD), highly impacting on quality-of-life and health-related costs.
OBJECTIVES: Aim of our real-world study was to evaluate the impact of Foslevodopa/Foscarbidopa (LDp/CDp) subcutaneous infusion (CSCI) on nocturia in a group of advanced PD patients.
METHODS: Seventy-eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale (IPSS) and Nocturia Quality of Life (NQoL) questionnaire were administrated before starting LDp/CDp CSCI and after three months of infusion.
RESULTS: In this cohort, LDp/CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS-UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post-pre changes of IPSS and LEED showed a negative correlation.
CONCLUSIONS: This study supports the utility of the overnight dopaminergic stimulation with LDp/CDp CSCI in controlling overactive bladder.
OBJECTIVES: Aim of our real-world study was to evaluate the impact of Foslevodopa/Foscarbidopa (LDp/CDp) subcutaneous infusion (CSCI) on nocturia in a group of advanced PD patients.
METHODS: Seventy-eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale (IPSS) and Nocturia Quality of Life (NQoL) questionnaire were administrated before starting LDp/CDp CSCI and after three months of infusion.
RESULTS: In this cohort, LDp/CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS-UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post-pre changes of IPSS and LEED showed a negative correlation.
CONCLUSIONS: This study supports the utility of the overnight dopaminergic stimulation with LDp/CDp CSCI in controlling overactive bladder.